Cargando…
Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with Lucentis in patients with neovascular age-related macular degeneration
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229946/ https://www.ncbi.nlm.nih.gov/pubmed/36872752 http://dx.doi.org/10.4103/IJO.IJO_2609_22 |
| _version_ | 1785051398694502400 |
|---|---|
| author | Shah, Chirag Sonkusare, Kishore |
| author_facet | Shah, Chirag Sonkusare, Kishore |
| author_sort | Shah, Chirag |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10229946 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Wolters Kluwer - Medknow |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102299462023-06-01 Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with Lucentis in patients with neovascular age-related macular degeneration Shah, Chirag Sonkusare, Kishore Indian J Ophthalmol Letters to the Editor Wolters Kluwer - Medknow 2023-03 2023-03-03 /pmc/articles/PMC10229946/ /pubmed/36872752 http://dx.doi.org/10.4103/IJO.IJO_2609_22 Text en Copyright: © 2023 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
| spellingShingle | Letters to the Editor Shah, Chirag Sonkusare, Kishore Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with Lucentis in patients with neovascular age-related macular degeneration |
| title | Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with Lucentis in patients with neovascular age-related macular degeneration |
| title_full | Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with Lucentis in patients with neovascular age-related macular degeneration |
| title_fullStr | Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with Lucentis in patients with neovascular age-related macular degeneration |
| title_full_unstemmed | Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with Lucentis in patients with neovascular age-related macular degeneration |
| title_short | Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s ranibizumab with Lucentis in patients with neovascular age-related macular degeneration |
| title_sort | response to commentary on: a prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of lupin’s ranibizumab with lucentis in patients with neovascular age-related macular degeneration |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229946/ https://www.ncbi.nlm.nih.gov/pubmed/36872752 http://dx.doi.org/10.4103/IJO.IJO_2609_22 |
| work_keys_str_mv | AT shahchirag responsetocommentaryonaprospectiverandomizedparallelgroupdoubleblindmulticenterstudytocomparetheefficacysafetyandimmunogenicityoflupinsranibizumabwithlucentisinpatientswithneovascularagerelatedmaculardegeneration AT sonkusarekishore responsetocommentaryonaprospectiverandomizedparallelgroupdoubleblindmulticenterstudytocomparetheefficacysafetyandimmunogenicityoflupinsranibizumabwithlucentisinpatientswithneovascularagerelatedmaculardegeneration |